Details

Autor(en) / Beteiligte

• O'Connor, Owen A
• Ansell, Stephen M
• Gribben, John G

Titel

Precision Cancer Therapies, Immunologic Approaches for the Treatment of Lymphoid Malignancies : From Concept to Practice

Auflage

1st ed

Ort / Verlag

Newark : John Wiley & Sons, Incorporated,

Erscheinungsjahr

2024

Link zum Volltext

• Wiley Online Library - AutoHoldings Books

Beschreibungen/Notizen

• Intro -- Precision Cancer Therapies -- Contents -- List of Contributors -- Volume Foreword -- Volume Preface -- Series Preface -- Section I Historical Perspective -- 1 The Distinguished History of Immunotherapy Development in Cancer -- Take Home Messages -- Introduction -- The Beginnings of Immunotherapy -- The Central Role of the Immune System -- Cytokines -- Antibody Based Therapy -- Immune Checkpoint Therapy -- Vaccines -- CAR T-cells and Adoptive Cell Therapy -- Summary -- Must Reads -- References -- Section II Targeting Cell Surface Receptors -- 2 Development of Monoclonal Antibodies for the Treatment of Lymphoma: Setting the Stage -- Take Home Messages -- Introduction -- Magic Bullets -- Monoclonal Antibodies -- Proof of Concept - Anti-idiotype mAb -- Chimeric, Humanized, and Human mAb -- Rituximab -- Anti-lymphoma mAb Mechanisms of Action -- Target Epitopes -- Enhancing mAb Effector Function -- Alternative Target Antigens -- Alternative Strategies to Leverage the Unique Aspects of mAb Therapy -- Radioimmunotherapy Based on Anti-sera -- Mab-based Radioimmunotherapy -- Radioimmunotherapy of B Cell Lymphoma -- Immunotoxins -- Antibody-drug Conjugates -- Retargeting T Cells -- Bispecific Antibodies -- Chimeric Antigen Receptor T Cells -- Bispecific Antibodies versus CAR-T -- Immune Checkpoint Blockade in Lymphoma -- Remaining Questions -- Conclusion -- Must Reads -- References -- 3 Pharmacology to Practice: The Similarities and Differences of Drugs Targeting CD20 -- Take Home Messages -- Introduction -- Anti-CD20 Monoclonal Antibody Development -- Rituximab -- Ofatumumab -- Ublituximab -- Obinutuzumab -- Resistance to Anti-CD20 Monoclonal Antibodies -- Combinations Using Bruton Tyrosine Kinase Inhibitor and Anti-CD20 Monoclonal Antibodies -- Radiolabeled Anti-CD20 Antibodies: I-131 Tositumomab and Y-90 Ibritumomab Tiuxetan.
• Anti-CD20 Antibody Drug Conjugates -- CD20 Bispecific Antibodies -- Anti-CD20 Chimeric Antigen Receptor (CAR) T-cell Therapy -- Conclusion -- Must Reads -- References -- 4 Pharmacology to Practice: Targeting CD19 and 22 -- Take Home Messages -- Introduction -- CD19 and CD22 Surface Antigens -- CD19 Antigen -- CD22 Antigen -- Therapeutic Targeting: CD19 -- Approved Agents Targeting CD19 -- Tafasitamab -- Pharmacokinetics and Pharmacodynamics -- Clinical Efficacy -- Safety and Tolerability -- Indication for Tafasitamab -- Loncastuximab Tesirine -- Introduction to Loncastuximab Tesirine -- Pharmacokinetics -- Pharmacodynamics and Distribution -- Clinical Efficacy -- Safety and Tolerability -- Indication for Loncastuximab Tesirine -- Emerging Agents Targeting CD19 -- Denintuzumab Mafodotin -- Bispecific Antibodies Targeting CD19 -- Sequencing CD19 Directed Therapies in the Treatment of R/R LBCL -- Therapeutic Targeting: CD22 -- Antibody Drug Conjugates Targeting CD22 -- Bispecific Antibody Targeting CD22 -- Summary -- Must Reads -- References -- 5 Targeting Other Promising Cell Surface Receptors: ROR1, CD38, CD25, and CCR4 -- Take Home Messages -- Introduction -- Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1) -- ROR1 Biology -- Role of ROR1 in Cancer -- Role of ROR1 in Hematologic Cancers -- Therapies Targeting ROR1 -- Safety of Therapies Targeting ROR1 -- Future Directions -- CD38 -- CD38 and Its Biological Functions -- CD38 Expression in Lymphoid Malignancies -- CD38-targeted Treatments in Lymphoid Malignancies -- The Interleukin 2 Receptor α Chain (CD25) -- The Biology of CD25 -- CD25 Pathophysiology -- Targeting CD25 as a Therapeutic Strategy -- C-C Motif Chemokine Receptor 4 (CCR4) -- CCR4 Targeting and Therapy -- CCR4 Expression in Normal and Cancerous Cells -- The Role of CCR4 in Immune Regulation -- CCR4 and Hematological Malignancies.
• CCR4 Targeting/Therapy -- Conclusions and Perspectives -- Must Reads -- References -- Section III Antibody Drug Conjugates (ADC) -- 6 Principles of Antibody Drug Development -- Take Home Messages -- Introduction -- Brief History -- Design Principles -- Target Antigen Selection -- Antibody Characteristics -- Cytotoxic Drug Potency -- Linker Selections and Conjugation Strategies -- ADCs Currently Approved for Lymphoid Malignancies -- Brentuximab Vedotin -- Inotuzumab Ozogamicin -- Polatuzumab Vedotin -- Belantamab Mafodotin -- Loncastuximab Tesirine -- Future -- Must Reads -- References -- 7 Targeting CD30 in Lymphoid Neoplasms -- Take Home Messages -- Introduction -- Receptor Function and Structure -- Strategies for Targeting CD30 -- Clinical Experience -- Conclusions and Future Directions -- Must Reads -- References -- 8 Targeting CD79b in B-cell Malignancies -- Take Home Messages -- Introduction -- Polatuzumab Vedotin Preclinical Development -- Clinical Results -- Phase 1 and 2 in Patients with Relapsed/Refractory (R/R) Lymphoma -- The Randomized Phase 2 Study in Patients with Relapsed or Refractory DLBCL -- Moving Polatuzumab Vedotin in the Front-line Management of DLBCL -- Polatuzumab Vedotin Combination in Other B-cell Lymphoma Histology -- Novel Investigational Combinations of Polatuzumab with Targeted Therapy -- Resistance Mechanisms to Polatuzumab Vedotin: Facts and Hypothesis -- Conclusion -- Must Reads -- References -- 9 Radioimmunotherapy: Is There Any Future Role? -- Take Home Messages -- Introduction -- Principles of Radioimmunotherapy in Non-Hodgkin Lymphomas -- 90Y-ibritumomab Tiuxetan -- Clinical Experience with 90Y-IT -- Lilotomab Satetraxetan -- Conclusion -- Must Reads -- References -- Section IV Targeting Immune Checkpoint -- 10 The Biology of Immune Checkpoint Blockade -- Take Home Messages -- Introduction.
• Recognition of Antigen -- T Cells -- NK Cells -- Failure of Immunosurveillance in Cancer -- Induction of Checkpoint Inhibitor Expression -- Mechanism of Action of Checkpoint Inhibitor Molecules -- Competition and Redirection of Costimulation -- Recruitment of Phosphatases -- SHP1/SHP2 Phosphatases -- PP2A -- Unresolved Mechanisms -- Mechanism of Action of Checkpoint Inhibitors -- Current Areas of Study -- Summary -- References -- 11 Mechanism of Action and Pharmacologic Features of Drugs Targeting PD-1/PDL-1 and CTLA-4 -- Take Home Messages -- Introduction -- Structure and Effector Functions of mAb Therapeutics -- Overview of PD-1 and PD-L1 Molecules -- Mechanisms of Action of PD-1 and PD-L1 Inhibitors -- Pharmacodynamic Effects of PD-1 and PD-L1 Inhibitors -- Overview of the CTLA4 Pathway -- Effects of CTLA-4 Blocking Mechanisms Mediated by anti-CTLA-4 mAbs -- Fc-dependent Mechanisms of anti-CTLA-4 mAbs -- Mechanisms of Action of ICB in B-cell Lymphomas -- Expression Pattern and Function of Immune Checkpoints in Normal GCs -- Expected Activity of ICB in B-cell Lymphomas Based on Immune Checkpoint Expression -- Future Outlook -- Must Reads -- References -- 12 Other Immune Checkpoint Targets of Interest -- Take Home Messages -- Introduction -- TIM-3 -- Structure and Signaling -- Ligands -- Galectin-9 -- Ceacam-1 -- HMGB1 -- Phosphatidylserine -- Expression and Function within the TME -- T Helper Cells -- T Regulatory Cells -- Cytotoxic T Cells -- Natural Killer Cells -- Monocytes and Macrophages -- Dendritic Cells -- Myeloid Derived Suppressor Cells -- Tumor Cells -- Translation into a Clinical Target -- Pre-clinical Models of TIM-3 Blockade -- Role as a Prognostic Marker -- Clinical Experience with TIM-3 Inhibitors -- LAG-3 -- Structure and Signaling -- Ligands -- MHC Class II -- Galectin-3 -- CLEC4G -- FGL1 -- Expression and Function within the TME.
• Effector CD4+ and CD8+ T Cells -- Tregs -- Other Cell Types -- Tumor Cells -- Translation into a Clinical Target -- Pre-clinical Models of LAG-3 Genetic Deficiency -- Pre-clinical Models of LAG-3 Blockade -- Role as a Prognostic Marker -- Clinical Experience with LAG-3 Inhibitors -- TIGIT -- Structure and Signaling -- Ligands -- CD155 -- CD112 -- CD226 -- Expression and Function within the TME -- Effector CD4+ and CD8+ T Cells -- Regulatory T Cell Populations -- NK Cells -- Translation into a Clinical Target -- Pre-clinical Models of TIGIT Blockade -- Role as a Prognostic Marker -- Clinical Experience with TIGIT Inhibitors -- Remaining Challenges and Opportunities -- Balancing Autoimmunity and Anti-tumor Efficacy -- Biomarkers for Treatment Response -- Other Immune Checkpoints -- Conclusions -- Conflicts of Interest -- Must Reads -- References -- 13 Clinical Experiences with Immune Checkpoint Inhibitors in Lymphomas -- Take Home Messages -- Rationale for Checkpoint Inhibitors in Lymphomas -- CTLA Blockade -- PD-1 Blockade -- Early Experiences with PD-1 Blockade in Hematologic Malignancies -- Phase II Registration Trials of PD-1 Blockade in Hodgkin Lymphoma: A Therapeutic Revolution -- Pivotal Trials of Nivolumab and Pembrolizumab in Hodgkin Lymphoma -- Real-world Data on PD-1 Blockade in Hodgkin Lymphoma -- Addition of PD-1 Blockade to Chemotherapy in Hodgkin Lymphoma: Combination with AVD -- Addition of PD-1 Blockade to Brentuximab Vedotin -- Which Is the Better Agent to Combine with AVD Chemotherapy in New HL: Nivolumab or Brentuximab Vedotin? -- Allogeneic Stem Cell Transplantation for Hodgkin Lymphoma in Era of PD-1 Blockade -- Other anti-PD-1 Antibodies Approved for Use in Hodgkin Lymphoma -- Phase I and II Trials of PD-1 Blockade in Non-Hodgkin Lymphoma -- Nivolumab -- Nivolumab Plus Ipilimumab in Lymphomas.
• Phase II Trials of Nivolumab in DLBCL and FL: Missing the Mark.
• Description based on publisher supplied metadata and other sources.